Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study) DOI Creative Commons
J Geldof, Marie Truyens, João Sabino

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(10), P. 1157 - 1157

Published: Oct. 11, 2024

Introduction: As the COVID-19 pandemic becomes an endemic state, still many questions remain regarding risks and impact of SARS-CoV-2 infection vaccination in patients with immune-mediated inflammatory diseases (IMIDs) who were excluded from phase 3 trials. Methods: The BELCOMID study collected patient data serological samples a large, multicentric IMID cohort that was prospectively followed during sequential stages pandemic. Patients stratified according to status into five groups across three sampling periods. Interactions between infection, status, IMID-treatment modalities course explored. Results: In total, 2165 IBD, dermatological or rheumatological participated. rates increased over highest had refused every vaccine. After baseline vaccination, serologic spike (S)-antibody responses attenuated by particular types immune-modulating treatment: anti-TNF, rituximab, JAKi, systemic steroids, combined biologic/immunomodulator treatment. Nonetheless, S-antibody concentration progressively received booster reaching 100% seroconversion rate two vaccines. Previous found as predictor higher response. vaccine showed lowest S-seroconversion (53.8%). Multiple logistic regression did not identify previous risk factor for flare-up. Furthermore, no flare-up vaccination. Conclusions: Altogether, provides evidence efficacy safety confirms importance repeated patients.

Language: Английский

Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study) DOI Creative Commons
J Geldof, Marie Truyens, João Sabino

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(10), P. 1157 - 1157

Published: Oct. 11, 2024

Introduction: As the COVID-19 pandemic becomes an endemic state, still many questions remain regarding risks and impact of SARS-CoV-2 infection vaccination in patients with immune-mediated inflammatory diseases (IMIDs) who were excluded from phase 3 trials. Methods: The BELCOMID study collected patient data serological samples a large, multicentric IMID cohort that was prospectively followed during sequential stages pandemic. Patients stratified according to status into five groups across three sampling periods. Interactions between infection, status, IMID-treatment modalities course explored. Results: In total, 2165 IBD, dermatological or rheumatological participated. rates increased over highest had refused every vaccine. After baseline vaccination, serologic spike (S)-antibody responses attenuated by particular types immune-modulating treatment: anti-TNF, rituximab, JAKi, systemic steroids, combined biologic/immunomodulator treatment. Nonetheless, S-antibody concentration progressively received booster reaching 100% seroconversion rate two vaccines. Previous found as predictor higher response. vaccine showed lowest S-seroconversion (53.8%). Multiple logistic regression did not identify previous risk factor for flare-up. Furthermore, no flare-up vaccination. Conclusions: Altogether, provides evidence efficacy safety confirms importance repeated patients.

Language: Английский

Citations

0